BONY-M 2期试验:寡转移骨转移SABR后的生活质量与疼痛反应
BONY-M 2期多中心试验纳入寡转移骨转移患者接受SABR,处方剂量为37.5或30 Gy分3次。有症状患者(基线NPRS≥2)24周疼痛缓解率为59%(13/22),52周为41%(9/22),24周平均疼痛评分下降2.4分(95%CI 1.6-3.3),第2周疼痛flare发生率为11%(7/66)。
要点
- SABR后1年内平均健康相关生活质量保持稳定。
- 有症状骨转移患者24周疼痛缓解率59%,52周41%。
- 第2周疼痛flare发生率11%。
核心结论
- 平均HRQoL在一年随访期间保持稳定,有症状转移灶获得预期疼痛缓解。
- 对经仔细选择的无症状和有症状OMD患者,SABR用于局部疾病控制不损害HRQoL。
研究设计与样本
- BONY-M为2期多中心试验(NCT05101824),纳入≥1处骨转移的寡转移疾病患者。
- 处方剂量为37.5或30 Gy分3次。
- 基线NPRS分组:无症状(NPRS 0-1)44例,有症状(NPRS≥2)22例。
主要发现
- 患者以前列腺癌(33%)、乳腺癌(28%)、肾癌(15%)、肺癌(10%)为主。
- EQ-5D-5L指数与VAS平均评分至52周随访保持稳定。
- 有症状患者基线与随访时报告更多疼痛/不适且EQ-5D-5L指数值低于无症状患者。
- 有症状患者总体疼痛缓解率24周为59%(13/22),52周为41%(9/22)。
- 有症状患者24周平均疼痛评分下降2.4分(95%CI 1.6-3.3)。
关键数值与推荐
- 疼痛反应评估使用数字疼痛评分量表(NPRS),基线及第2、12、24、36、52周采集。
- HRQoL评估使用EuroQol EQ-5D-5L,基线及第12、24、36、52周采集。
- 第2周疼痛flare发生率为11%(7/66)。
临床怎么用
- 对经选择的寡转移骨转移患者,SABR可作为局部控制选项而不损害一年内平均HRQoL。
- 有症状骨转移患者可预期疼痛缓解,但需关注第2周疼痛flare。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Bony-M phase 2 multicentre trial included patients with oligometastatic disease (OMD) for stereotactic ablative radiotherapy (SABR) of bone metastases (clinicaltrials.gov ID-no.NCT05101824). We report the secondary endpoint analyses of longitudinal health-related quality of life (HRQoL) outcomes and pain response. METHODS: Patients with ≥ 1 bone metastasis were eligible for inclusion. Prescription doses were 37.5 or 30 Gy in three fractions. EuroQol EQ-5D-5L and numeric pain rating scale (NPRS) responses were collected at baseline and weeks 12, 24, 36, and 52 (pain also at week 2). For this analysis, patients were grouped by baseline NPRS as being either asymptomatic (NPRS 0-1) or symptomatic (NPRS ≥ 2). RESULTS: Sixty-seven patients were analysed, including one patient without baseline NPRS. Most had prostate (33 %), breast (28 %), kidney (15 %), or lung cancer (10 %). Mean EQ-5D-5L index and visual analogue scale scores remained stable through 52 weeks of follow-up. Symptomatic patients (n = 22) reported more pain/discomfort and had a lower EQ-5D-5L index value at baseline and follow-up than asymptomatic patients (n = 44). Among symptomatic patients, overall pain response was 59 % (13/22) at 24 weeks and 41 % (9/22) at 52 weeks. Mean pain score decreased by 2.4 points (95 % CI: 1.6-3.3) at 24 weeks. Pain flare at week 2 occurred in 11 % (7/66) of patients. CONCLUSIONS: Mean HRQoL remained stable throughout one year of follow-up, and expected pain relief was achieved for symptomatic metastases. Our findings suggest that SABR for local disease control in carefully selected patients with asymptomatic and symptomatic OMD can be used without compromising HRQoL.
引用
- Spindler NJ, Krog SM, Felter MVO, et al. Quality of life and pain-response after stereotactic ablative radiotherapy of oligometastatic bone metastases in the phase 2 BONY-M trial. Radiother Oncol. 2026. PMID: 42727887. doi:10.1016/j.radonc.2026.111774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。